2. Search Result
Search Result
Results for "

GnRH receptor antagonist

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

7

Peptides

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-107534
    AG-045572

    		GnRH Receptor Endocrinology
    AG-045572 is a GnRH receptor antagonist with Kis of 6.0 nM and 3.8 nM for human and rat GnRH receptor, respectively. AG-045572 is metabolized by CYP3A and ressuppresses testosterone .
    AG-045572
  • HY-134864
    GnRH antagonist 2

    		GnRH Receptor Endocrinology
    GnRH antagonist 2 (formula I) is a GnRH receptor antagonist that can be used for endometriosis research .
    GnRH antagonist 2
  • HY-133080
    BAY-784

    		GnRH Receptor Cancer
    BAY-784 is a gonadotropin releasing hormone receptor (GnRH-R) antagonist probe with IC50s of 21 and 24 nM for human and rat GnRH-R, respectively .
    BAY-784
  • HY-P0009A
    Cetrorelix Acetate
    1 Publications Verification

    SB-75 acetate

    		 GnRH Receptor Neurological Disease Endocrinology
    Cetrorelix Acetate (SB-75 acetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM .
    Cetrorelix Acetate
  • HY-P2028
    BIM 21009

    		GnRH Receptor Cancer
    BIM 21009 is a LHRH and GnRH receptor antagonist. BIM 21009 inhibits tumor growth .
    BIM 21009
  • HY-105173
    Teverelix

    EP 24332

    		 GnRH Receptor Histamine Receptor Endocrinology Cancer
    Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .
    Teverelix
  • HY-P0009B
    Cetrorelix diacetate

    SB-75 diacetate

    		 GnRH Receptor Neurological Disease Endocrinology
    Cetrorelix diacetate (SB-075 diacetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM .
    Cetrorelix diacetate
  • HY-U00289
    Opigolix

    ASP-1707

    		 GnRH Receptor Inflammation/Immunology Endocrinology
    Opigolix (ASP-1707) is a Gonadotropin-releasing hormone (GnRH) receptor antagonist, used for the research of endometriosis and rheumatoid arthritis.
    Opigolix
  • HY-14369R
    Elagolix sodium (Standard)

    		GnRH Receptor Endocrinology Cancer
    Elagolix sodium (Standard) is the analytical standard of Elagolix sodium. This product is intended for research and analytical applications. Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with an IC50 and Ki of 0.25 and 3.7 nM, respectively.
    Elagolix sodium (Standard)
  • HY-P3317
    Azaline

    Azaline A

    		 GnRH Receptor Endocrinology
    Azaline (Azaline A) is a gonadotropin-releasing hormone (GnRH) receptor antagonist with a KD value of 0.48 nM. Azaline can effectively induce histamine release, with an effect comparable to that of GnRH, and it can completely inhibit ovulation at a dose of 2.0-3.0 μg per female rat. Azaline has potential applications in regulating reproductive functions .
    Azaline
  • HY-14369S
    Elagolix-13C,d3 sodium

    NBI-56418-13C,d3 sodium

    		 Isotope-Labeled Compounds GnRH Receptor Endocrinology Cancer
    Elagolix- 13C,d3 (sodium) is the 13C- and deuterium labeled Elagolix sodium. Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with an IC50 and Ki of 0.25 and 3.7 nM, respectively.
    Elagolix-13C,d3 sodium
  • HY-14369
    Elagolix sodium

    NBI-56418 sodium

    		 GnRH Receptor Nuclear Factor of activated T Cells (NFAT) Endocrinology Cancer
    Elagolix sodium is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
    Elagolix sodium
  • HY-14789
    (R)-Elagolix

    NBI-56418

    		 GnRH Receptor Nuclear Factor of activated T Cells (NFAT) Endocrinology Cancer
    Elagolix is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
    (R)-Elagolix
  • HY-109532
    Ganirelix acetate

    Ganirest

    		 GnRH Receptor Metabolic Disease
    Ganirelix acetate (Ganirest) is an injectable competitive gonadotropin-releasing hormone (GnRH) antagonist. Ganirelix acetate directly competes against the endogenous molecule for receptor binding, and causes a rapid reduction in estradiol levels. Ganirelix acetate can be used for researching ovarian hyperstimulation syndrome (OHSS) .
    Ganirelix acetate
  • HY-13699
    NBI-42902

    		GnRH Receptor PERK Others
    NBI-42902 is an orally active, potent functional and competitive antagonist of GnRH receptor with an IC50 value of 0.79 nM, a Ki value of 0.56 nM, respectively. NBI-42902 inhibits GnRH-stimulated inositol phosphate (IP) accumulation, Ca 2+ flux, and ERK1/2 activation. NBI-42902 inhibits serum luteinizing hormone (LH) in castrated male macaques. NBI-42902 can be used for research on sex-hormone-related diseases .
    NBI-42902
  • HY-120767
    Linzagolix choline

    KLH-2109 choline; OBE-2109 choline

    		 GnRH Receptor Inflammation/Immunology Cancer
    Linzagolix choline (KLH-2109 choline) is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist with oral activity. Linzagolix choline inhibits the release of endogenous gonadotropins such as luteinizing hormone LH and follicle-stimulating hormone FSH by binding to the GnRH receptor within the pituitary gland. This inhibition results in a reduction in the production of sex hormones such as estrogen and progesterone, which in turn affects the course of sex hormone-dependent diseases. Linzagolix choline can be used in the study of sex hormone-dependent diseases such as endometriosis and uterine fibroids .
    Linzagolix choline
  • HY-W751574
    Elagolix-d6 sodium

    NBI-56418-d6 sodium

    		 Isotope-Labeled Compounds Nuclear Factor of activated T Cells (NFAT) GnRH Receptor Endocrinology Cancer
    Elagolix-d6 (sodium) (NBI-56418-d6 (sodium)) is deuterium labeled Elagolix sodium. Elagolix sodium is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
    Elagolix-d6 sodium
  • HY-P2446
    ORG 30276

    APTAA-LHRH

    		 GnRH Receptor Endocrinology
    ORG 30276 (APTAA-LHRH) is a potent GnRH antagonist that effectively reduces serum LH and FSH levels in male rats. ORG 30276 significantly decreases unoccupied pituitary GnRH receptors, leading to suppressed gonadotropin secretion. ORG 30276 treatment results in a considerable reduction in mRNA levels of gonadotropin beta-subunits in the pituitary gland. ORG 30276's effects on gonadotropin dynamics can be selectively reversed by the replacement of specific sex steroids, with androgens being particularly effective for the FSH beta-subunit mRNA levels.
    ORG 30276
  • HY-16474
    Relugolix

    TAK-385

    		 GnRH Receptor Endocrinology Cancer
    Relugolix (TAK-385)?is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209) . Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al .
    Relugolix
  • HY-P3671
    [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH

    		GnRH Receptor Endocrinology
    [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH acts as a GnRH receptor antagonist .
    [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH
  • HY-16474R
    Relugolix (Standard)

    		GnRH Receptor Endocrinology Cancer
    Relugolix (Standard) is the analytical standard of Relugolix. This product is intended for research and analytical applications. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209) . Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al .
    Relugolix (Standard)
  • HY-16474S
    Relugolix-d6

    TAK-385-d6

    		 Isotope-Labeled Compounds GnRH Receptor Endocrinology Cancer
    Relugolix-d6 is deuterium labeled Relugolix. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209)[1]. Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al[2].
    Relugolix-d6
  • HY-117982
    SKI2496

    		GnRH Receptor ERK Endocrinology
    SKI2496 is an orally active GnRH receptor antagonist (IC50: 0.25 nM for hGnRHR, 13.2 nM for monkey GnRHR, 279.2 nM for rat GnRHR). SKI2496 blocks Ca 2+ flux with an IC50 value of 0.76 nM. SKI2496 inhibits ERK1/2 phosphorylation with an IC50 value of 2.6 nM. SKI2496 inhbits serum LH concentrations, and can be used for research of sex hormone-dependent disorders .
    SKI2496

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: